The prevalence of metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, and obstructive sleep ...

New research has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes -- not the presence of certain fats, but their suppression. The study challenges the ...

New research from Weill Cornell Medicine has uncovered a surprising culprit underlying cardiovascular diseases in obesity and ...

Urgent action needed to tackle the rising obesity //burden . Obesity is more than a cosmetic concern - it's a major health challenge silently affecting millions around the world ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Drinking sugar-sweetened beverages may increase your risk of heart disease. These drinks are easy to overconsume and provide ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Obesity remains a global health crisis, often linked to serious diseases such as diabetes, heart disease, and fatty liver ...

The Trump administration is not finalizing a Biden-era provision that would expand coverage of anti-obesity drugs under Medicare and Medicaid, which has disappointed some healthcare leaders.

The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...